Burta Mihai Cosmin, Avram Adela, Avram Radu Florian, Rogers Steven Kristofor, Bowling Frank Lee, Ionac Stefan, Ionac Mihai Edmond
Faculty of Medicine, Victor Babes University of Medicine and Pharmacy, 300041 Timișoara, Romania.
ArTerra Health Clinic, 300402 Timișoara, Romania.
J Clin Med. 2025 Aug 31;14(17):6165. doi: 10.3390/jcm14176165.
The introduction of radial-firing laser fibers has minimized catheter-to-vein distance during endovenous laser ablation (EVLA) for the great saphenous vein (GSV) and anterior saphenous veins (ASVs). This study investigates flush endovenous laser ablation (fEVLA) effectiveness in addressing chronic superficial venous insufficiency (CVI). This single-center retrospective study analyzed consecutive fEVLA cases with duplex ultrasound follow-up at 1, 4, and 12 weeks. The primary endpoint was clinically significant endovenous heat-induced thrombosis (classes III-IV). Three hundred and twelve patients were recruited (405 affected limbs, 369 GSV, and 36 ASV). CEAP classifications were stratified as follows: C2 in 6.1%, C3 in 34.2%, C4 in 44%, C5 in 2.7%, and C6 in 12.7% of cases. Perforator ligation, phlebectomy, or foam sclerotherapy were carried out in conjunction with EVLA. fEVLA was feasible in all cases. The success rate was 96.78%, defined as EHIT classes 1 and 2, and assessed by ultrasound one week postoperatively. Clinically significant EHIT (2.5% class 3 and 0.2% class 4) was managed with 15 mg rivaroxaban twice daily for 21 days. Follow-up at 4 weeks revealed complete resolution of all EHIT 3-4 cases. No cases of pulmonary embolism or deep vein thrombosis were observed during the study or follow-up period. fEVLA is a safe treatment for superficial CVI across various CEAP classes, and with prompt detection, the minimal complication rate can be completely resolved.
径向发射激光光纤的引入,已将大隐静脉(GSV)和前隐静脉(ASV)腔内激光消融术(EVLA)期间导管与静脉的距离降至最低。本研究调查了冲洗式腔内激光消融术(fEVLA)治疗慢性下肢浅静脉功能不全(CVI)的有效性。这项单中心回顾性研究分析了连续接受fEVLA治疗且在1周、4周和12周进行双功超声随访的病例。主要终点是具有临床意义的腔内热诱导血栓形成(III-IV级)。共纳入312例患者(405条患肢,369条GSV和36条ASV)。CEAP分级分层如下:C2级占6.1%,C3级占34.2%,C4级占44%,C5级占2.7%,C6级占12.7%。在进行EVLA的同时进行了交通静脉结扎、静脉切除术或泡沫硬化疗法。fEVLA在所有病例中均可行。成功率为96.78%,定义为EHIT 1级和2级,术后1周通过超声评估。对于具有临床意义的EHIT(2.5%为3级,0.2%为4级),给予利伐沙班15 mg,每日两次,共21天。4周随访显示所有EHIT 3-4级病例均完全消退。在研究或随访期间未观察到肺栓塞或深静脉血栓形成病例。fEVLA是一种治疗各种CEAP分级的浅表CVI的安全方法,并且通过及时检测,可将最低并发症发生率完全解决。